Clinical quality assurance for 106Ru ophthalmic applicators.
OBJECTIVE
Episcleral brachytherapy using 106Ru/106Rh ophthalmic applicators is a proven method of therapy of uveal melanomas sparing the globe and in many cases sparing the vision. In the year 2001, an internal clinical quality assurance procedure revealed that part of the ophthalmic applicators leaked and that the calibration was erroneous. Consequently, the producer modernized its production procedures and, in May 2002, introduced a dose rate calibration that is traceable to the NIST standard. This NIST calibration confirmed that the previous calibration had been incorrect. In order to study the effects of the producer's new internal quality assurance procedures on the ophthalmic applicators, applicators of this new generation were submitted to a newly improved internal clinical acceptance test.


METHODS
The internal clinical acceptance test consists of a leakage test and a dosimetric test of the ophthalmic applicators. The leakage test simulates contact of the ophthalmic applicators with chloride containing body fluid. The dosimetric tests measure depth dose curves and dose rate with a plastic scintillator dosimetric system and compare them with the indications in the producer's certificate. Furthermore, the depth dose profile of the most frequently used applicator (type CCB) was compared with published data.


RESULTS
The internal clinical leakage test showed that all of the tested ophthalmic applicators belonging to the new generation (n=17) were tight and not contaminated. The dosimetric acceptance tests applied to seven different types of applicators revealed that the relative depth dose profiles in the therapeutically relevant range (up to a depth of <or=7 mm) deviate from the producer's indications only by -2.7 to +3.2%. The acceptance test of the dose rate values of the ophthalmic applicators at a distance of 2mm from the surface of the applicators resulted in a coefficient of variation of 1.7% (n=17). In the evaluation of the depth dose profile of the type CCB applicator the producer's indications and the results of the entrance test conformed very well to published data.


CONCLUSIONS
The internal clinical quality assurance procedure has proved successful in three ways. (1) It had a catalytic effect that led to the development of a new generation of ophthalmic applicators. (2) It could be demonstrated that this new generation of applicators is up to the state of the art in brachytherapy. (3) With this new generation of 106Ru/106Rh ophthalmic applicators it is possible for the first time in the history of their use to apply the dose that is prescribed by the radiooncologist.
Kaulich
Theodor W
TW
Medical Physics, University of Tübingen, Germany. theodor.kaulich@med.uni-tuebingen.de
Zurheide
Jens
J
Haug
Thomas
T
Nüsslin
Fridtjof
F
Bamberg
Michael
M
D001918:Brachytherapy / Q000295:instrumentation* / Q000592:standards; D002138:Calibration; D006801:Humans; D008545:Melanoma / Q000532:radiotherapy*; D011786:Quality Control; D011879:Radiotherapy Dosage; D012429:Ruthenium Radioisotopes / Q000627:therapeutic use*; D014604:Uveal Neoplasms / Q000532:radiotherapy*
D012429:Ruthenium Radioisotopes